Amgen Enbrel “Black Box” Warning Being Considered By FDA
Executive Summary
FDA may require that a "black box" warning be added to labeling for the tumor necrosis factor inhibitor Enbrel (etanercept), in line with other agents in the class, Amgen Senior VP-North America Commercial Operations James Daly said during a Nov. 13 meeting with Amgen management hosted by Bear Stearns